| Pelabresib (BET bromodomain inhibitor) |
biorxiv |
pelabresib CPI-0610 BET bromodomain myelofibrosis |
Targets pelabresib (CPI-0610) specifically by both brand name and compound ID alongside BET bromodomain and myelofibrosis, distinct from the existing INCB057643 BET query which covers a different BET inhibitor compound. |
manually-archived |
| Pelabresib (BET bromodomain inhibitor) |
pubmed |
"pelabresib"[Title/Abstract] OR "CPI-0610"[Title/Abstract] |
Targets pelabresib by both its generic name and trial compound identifier, which existing queries (including the BET bromodomain inhibitor query) do not explicitly cover, ensuring retrieval of all clinical and preclinical papers on this specific agent. |
active |
| Phlebotomy-only maintenance in PV |
biorxiv |
phlebotomy polycythemia vera hematocrit cytoreduction low-risk treatment outcome |
Targets phlebotomy-only management strategy in PV specifically, which is not covered by existing queries that focus on drug therapies, JAK2 signaling, or thrombosis risk factors. |
manually-archived |
| Phlebotomy-only maintenance in PV |
pubmed |
"phlebotomy"[Title/Abstract] AND ("polycythemia vera"[Title/Abstract] OR "polycythaemia vera"[Title/Abstract]) AND ("low-risk"[Title/Abstract] OR "hematocrit"[Title/Abstract] OR "cytoreduction"[Title/Abstract] OR "aspirin"[Title/Abstract] OR "monotherapy"[Title/Abstract]) |
Targets phlebotomy as a standalone or primary treatment strategy in PV specifically, which no existing query covers — existing hydroxyurea query touches cytoreduction but not phlebotomy-only management. |
active |
| Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain |
biorxiv |
JAK2V617F pseudokinase JH2 allosteric inhibitor mutant-selective |
Targets the specific mechanistic concept of JH2 pseudokinase domain-directed mutant-selective JAK2V617F inhibition, which no existing query covers; distinct from the broader JAK2 STAT signaling query and from active-site/Type II inhibitor queries. |
manually-archived |
| Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain |
pubmed |
"JH2"[Title/Abstract] AND ("pseudokinase"[Title/Abstract] OR "allosteric"[Title/Abstract]) AND ("JAK2"[Title/Abstract] OR "JAK2V617F"[Title/Abstract] OR "V617F"[Title/Abstract]) |
Targets the JH2 pseudokinase domain allosteric mechanism specifically, which no existing query covers — existing queries address JAK-STAT signaling broadly or ruxolitinib/pan-JAK inhibitors but not the mutant-selective JH2-directed inhibition concept. |
demoted |
| Bone marrow fibrosis |
biorxiv |
bone marrow fibrosis reticulin collagen myelofibrosis stroma progression |
Targets the stromal/fibrotic mechanism specific to bone marrow fibrosis in MPN, which none of the existing queries address directly. |
manually-archived |
| Bone marrow fibrosis |
pubmed |
"bone marrow fibrosis"[Title/Abstract] AND ("reticulin"[Title/Abstract] OR "collagen fibrosis"[Title/Abstract] OR "fibrosis grade"[Title/Abstract] OR "TGF-beta"[Title/Abstract] OR "transforming growth factor"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR myeloproliferative[Title/Abstract]) |
Targets the mechanistic drivers and grading of marrow fibrosis (reticulin, collagen, TGF-beta) specifically in MPNs, which no existing query addresses. |
active |